Evidence map›Paper›PMID 30759003›Full record

ReviewAnnals of the American Thoracic Society2018

Chronic Obstructive Pulmonary Disease and Pulmonary Vascular Disease. A Comorbidity?

Norbert Weissmann

Abstract readReview
In one paragraph

Review in Annals of the American Thoracic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Differentiation and Growth-Arrest-Related lncRNA (International journal of molecular sciences · 2024
    Article
  4. Observational
  5. Article
  6. Review
  7. Factors Associated with Chronic Obstructive Pulmonary Disease: A Hospital-Based Case-Control Study.International journal of chronic obstructive pulmonary disease · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Observational
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Norbert WeissmannJustus Liebig University Giessen, Excellence Cluster Cardio-Pulmonary System (ECCPS), Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; and member of the German Center for Lung Research (DZL), Germany.
Justus-Liebig-Universität Gießen · DE

Funding

Aspen Lung Conference on COPD: Translating Resilience and Pathogenesis to Personalized Therapy for COPDR13HL142192 · NHLBI · NATIONAL JEWISH HEALTH · PI PETRACHE, IRINA, VANDIVIER, RICHARD W · 2018 to 2018
$30k
NHLBI NIH HHS R13 HL142192
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most important causes of death worldwide, and in addition to its impact on the patient's health, it poses a major socioeconomic burden. Tobacco smoke, indoor cooking, and air pollution are major triggers of the disease. This article summarizes evidence for the concept that lung microvascular molecular alterations can be a driver of lung emphysema. If findings from preclinical models allow a transfer to the human situation, this concept can offer new approaches for curative treatment of lung emphysema.

Indexed as

Airway RemodelingAnimalsComorbidityDisease Models, AnimalEndothelium, VascularHumansHypertension, PulmonaryMicePulmonary ArteryPulmonary CirculationPulmonary Disease, Chronic ObstructivePulmonary EmphysemaTobacco SmokingVascular Diseaseschronic obstructive pulmonary diseaseinducible nitric oxide synthaselung regenerationpulmonary hypertensionsoluble guanylate cyclase

Identifiers

PMID30759003
PMCPMC6944394
OpenAlexW2904387191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.